Last $14.86 USD
Change Today -0.105 / -0.70%
Volume 610.0K
DEPO On Other Exchanges
As of 2:33 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

depomed inc (DEPO) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/27/14 - $15.51
52 Week Low
10/9/13 - $6.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DEPOMED INC (DEPO)

depomed inc (DEPO) Related Businessweek News

No Related Businessweek News Found

depomed inc (DEPO) Details

Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other conditions, and diseases of the central nervous system in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Lazanda (fentanyl) Nasal Spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is also involved in the clinical development of DM-1992 that completed a Phase II trial for Parkinson's disease. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. It has license and collaboration agreements with Abbott Products Inc.; Santarus, Inc.; Boehringer Ingelheim International GMBH; Ironwood Pharmaceuticals, Inc.; Janssen Pharmaceutica N.V.; Janssen Pharmaceuticals, Inc.; Mallinckrodt; Patheon Puerto Rico, Inc.; and Valeant Pharmaceuticals International, Inc. The company was founded in 1995 and is headquartered in Newark, California.

291 Employees
Last Reported Date: 03/17/14
Founded in 1995

depomed inc (DEPO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $590.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $363.9K
Senior Vice President and General Counsel
Total Annual Compensation: $380.0K
Senior Vice President of Business Development
Total Annual Compensation: $327.8K
Compensation as of Fiscal Year 2013.

depomed inc (DEPO) Key Developments

Update On DepoMed’s Acquisition Plans; Raises Convertible Note Offering To $300 million

DepoMed Inc. (NasdaqGS:DEPO) is looking for acquisitions. The company has raised the size of its sale of convertible senior notes to $300 million from the initial $230 million. It said it will raise net proceeds of $334 million and the funds will be used for working capital and potentially for strategic acquisitions.

DepoMed Seeks Acquisitions

DepoMed Inc. (NasdaqGS:DEPO) intends to pursue acquisitions. Depomed intends to offer $230 million aggregate principal amount of Convertible Senior Notes due 2021. The company intends to use the funds for working capital and other general corporate purposes and potential acquisitions and strategic transactions.

DepoMed Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 02:40 PM

DepoMed Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 02:40 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: James A. Schoeneck, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DEPO:US $14.86 USD -0.105

DEPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $17.07 USD -0.28
Emergent Biosolutions Inc $21.89 USD -0.31
Horizon Pharma Plc $12.69 USD +0.32
Insys Therapeutics Inc $33.86 USD -0.21
Skyepharma PLC 310.25 GBp +1.75
View Industry Companies

Industry Analysis


Industry Average

Valuation DEPO Industry Range
Price/Earnings 11.3x
Price/Sales 3.9x
Price/Book 4.9x
Price/Cash Flow 10.1x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEPOMED INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at